CD8A and neoplasm: Moreover, patients with Luminal-CD8+Thigh subtype were characterized by the amplification of PPARG. Notably, a pre-clinical study demonstrated that the downregulation of PPARG expression levels using a PPARγ-inhibitor led to an anti-proliferative effect on tumor cells [29].